감염성 호흡기질환 진단 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 기술별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Infectious Respiratory Disease Diagnostics Market Size, Share & Trends Analysis By Product, By Application, By Technology, By End-use, By Region, And Segment Forecasts, 2026 - 2033

US $ 5,950 ￦ 8,888,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,381,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,369,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

감염성 호흡기질환 진단 시장 요약

세계의 감염성 호흡기질환 진단 시장 규모는 2025년 125억 6,000만 달러로 추정되며, 2033년까지 157억 달러에 이를 것으로 예측됩니다.

또한 2026-2033년 연평균 복합 성장률(CAGR) 2.90%를 나타낼 것으로 예측됩니다. 이 시장은 결핵 및 폐렴과 같은 질병 증가, 진단 기술의 발전, 주요 기업간의 제휴 및 협력 관계 강화 등 몇 가지 주요 요인에 의해 주도되고 있습니다.

예를 들어, 2023년 2월 써모피셔 사이언티픽과 마이러브 디스커버리 솔루션즈는 인도에서 다제내성 결핵, B형 간염 바이러스, C형 간염 바이러스, HIV, 유전자 분석(HLA B27) 등 감염성 질환에 대한 진단검사 키트 개발 및 판매에 관한 제휴를 발표하였습니다. 이번 협력은 Thermo Fisher의 세계 전문성과 MyLab의 현지 제조 역량을 결합하여 고품질 검사 솔루션에 대한 접근성을 확대하는 것을 목표로 하고 있습니다.

결핵 진단 프로그램에 대한 자금 지원 확대는 이 세계적인 질병과의 싸움에서 매우 중요합니다. 현재 예방, 진단, 치료에 대한 자금은 수요를 충족시키기에 충분하지 않아 이환율과 사망률 감소를 위한 진전을 가로막고 있습니다. 예를 들어, 2027년까지 연간 220억 달러의 투자가 설정되어 있고, 조사에 50억 달러가 추가로 배정된 반면, 결핵 서비스에는 58억 달러만 배정되어 세계 목표 달성에 필요한 금액에 미치지 못하고 있습니다. 또한, WHO는 결핵을 효과적으로 퇴치하기 위해서는 지속적이고 확대된 자금 지원이 필요하다고 강조하고 있습니다. 이에 따라 미국 정부는 결핵 퇴치를 위한 예산을 대폭 증액하여 2013년 2억 3,300만 달러에서 2023년 4억 6,000만 달러로 확대했습니다. 선별검사 및 예방적 치료에 대한 투자는 1달러 지출 시 최대 39달러의 투자수익률(ROI)을 가져오는 등 건강 및 경제적인 측면에서 뚜렷한 효과를 나타내고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 감염성 호흡기질환 진단 시장 변수, 동향, 범위

제4장 감염성 호흡기질환 진단 시장 : 제품별 추정 및 동향 분석

제5장 감염증 호흡기질환 진단 시장 : 기술별 추정 및 동향 분석

제6장 감염성 호흡기질환 진단 시장 : 용도별 추정 및 동향 분석

제7장 감염성 호흡기질환 진단 시장 : 최종 용도별 추정 및 동향 분석

제8장 감염성 호흡기질환 진단 시장 : 지역별 추정 및 동향 분석

제9장 경쟁 구도

LSH

영문 목차

영문목차

Infectious Respiratory Disease Diagnostics Market Summary

The global infectious respiratory disease diagnostics market size was estimated at USD 12.56 billion in 2025 and is projected to reach USD 15.70 billion by 2033, growing at a CAGR of 2.90% from 2026 to 2033. The market is being driven by several key factors, including the growing prevalence of diseases like tuberculosis and pneumonia, advancements in diagnostic technologies, and increased partnerships and collaborations between major players.

For instance, in February 2023, Thermo Fisher Scientific and Mylab Discovery Solutions announced a partnership to develop and distribute diagnostic test kits for infectious diseases such as multi-drug-resistant tuberculosis, hepatitis B virus, hepatitis C virus, HIV, and genetic analysis (HLA B27) in India. The collaboration aims to combine Thermo Fisher's global expertise with Mylab's local manufacturing capabilities to expand access to high-quality testing solutions.

The increasing funding for TB diagnosis programs is crucial in the fight against this global disease. The current funding for prevention, diagnosis, and treatment is insufficient to meet the demand, hindering progress in reducing incidence & mortality rates. For instance, an annual investment of USD 22 billion by 2027 was set, with an additional USD 5 billion for research, and only USD 5.8 billion was allocated for TB services, falling short of the required amounts to achieve global targets. Moreover, WHO emphasizes the need for sustained & increased funding to combat TB effectively. Hence, the U.S. government has significantly increased its funding for TB initiatives, from USD 233 million in 2013 to USD 406 million in 2023. Investments in screening and preventive treatment have shown significant health & economic benefits, with a return on investment of up to USD 39 for every dollar spent.

Global Infectious Respiratory Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global infectious respiratory disease diagnostics market report based on technology, pathogen, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Reagents
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• COVID-19
• Influenza
• Respiratory Syncytial Virus (RSV)
• Tuberculosis
• Non-tuberculosis Mycobacterium Testing
• Bacterial Pneumonia Testing
• Other Respiratory Disease Testing
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Immunoassay
• Molecular Diagnostics
• Microbiology
• Rapid/Point-of-Care Diagnostics
• Other Technologies
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Clinics
• Research Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Product
  • 1.2.3. End Use
  • 1.2.4. Application
  • 1.2.5. Regional Scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Infectious Respiratory Disease Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. High Prevalence Of Infectious Respiratory Diseases Globally
    • 3.2.1.2. Technological Advancement In Respiratory Disease Testing
    • 3.2.1.3. Rising R&D Investments In Respiratory Disease Testing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Prices Of Diagnostic Products
    • 3.2.2.2. Presence Of Ambiguous Regulatory Framework
• 3.3. Infectious Respiratory Disease Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Infectious Respiratory Disease Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Infectious Respiratory Disease Diagnostics Market: Product Movement Analysis
• 4.3. Infectious Respiratory Disease Diagnostics Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
• 4.5. Instruments
  • 4.5.1. Instruments Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Reagents
  • 4.6.1. Reagents Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Services
  • 4.7.1. Services Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Infectious Respiratory Disease Diagnostics Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Infectious Respiratory Disease Diagnostics Market: Technology Movement Analysis
• 5.3. Infectious Respiratory Disease Diagnostics Market by Technology Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
• 5.5. Immunoassay
  • 5.5.1. Immunoassay Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Molecular Diagnostics
  • 5.6.1. Molecular Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Microbiology
  • 5.7.1. Microbiology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Rapid/Point-of-Care Diagnostics
  • 5.8.1. Microbiology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Other Technologies
  • 5.9.1. Other Technologies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Infectious Respiratory Disease Diagnostics Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Infectious Respiratory Disease Diagnostics Market: Application Movement Analysis
• 6.3. Infectious Respiratory Disease Diagnostics Market by Application Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
• 6.5. COVID-19
  • 6.5.1. COVID-19 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Influenza
  • 6.6.1. Influenza Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Respiratory Syncytial Virus
  • 6.7.1. Respiratory Syncytial Virus Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Tuberculosis
  • 6.8.1. Tuberculosis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Non-tuberculosis Mycobacterium Testing
  • 6.9.1. Non-tuberculosis Mycobacterium Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.10. Bacterial Pneumonia Testing
  • 6.10.1. Bacterial Pneumonia Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.11. Other Respiratory Disease Testing
  • 6.11.1. Other Respiratory Disease Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Infectious Respiratory Disease Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Infectious Respiratory Disease Diagnostics Market: End Use Movement Analysis
• 7.3. Infectious Respiratory Disease Diagnostics Market by End Use Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
• 7.5. Hospitals
  • 7.5.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Diagnostic Laboratories
  • 7.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Research Institutes
  • 7.7.1. Research Institutes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Clinics
  • 7.8.1. Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Infectious Respiratory Disease Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Recent Developments & Impact Analysis by Key Market Participants
• 9.3. Company Market Share Analysis, 2025
• 9.4. Key Company Profiles
  • 9.4.1. ABBOTT
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. F. Hoffmann - La Roche Ltd
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. BD
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. KONINKLIJKE PHILIPS N.V.
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. BIOMERIEUX SA
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. BIO-RAD LABORATORIES, INC.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. QUIDEL CORPORATION
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. CEPHEID
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. QIAGEN
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. SIEMENS HEALTHCARE GMBH
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Seegene Inc.
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. EliTechGroup (Bruker Corporation)
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives
  • 9.4.13. CERTEST BIOTEC
    • 9.4.13.1. Company overview
    • 9.4.13.2. Financial performance
    • 9.4.13.3. Product benchmarking
    • 9.4.13.4. Strategic initiatives
  • 9.4.14. Thermo Fisher Scientific, Inc.
    • 9.4.14.1. Company overview
    • 9.4.14.2. Financial performance
    • 9.4.14.3. Product benchmarking
    • 9.4.14.4. Strategic initiatives

관련자료